Cadrenal Therapeutics, Inc. Common Stock
CVKDHealthcare|Biotechnology|US
$0.98
-0.02 (-2.00%)
DCF Value
$1.73
Tangible Book / Share
$1.40
Cash / Share
$0.82
About
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Stock Price
-92.0%(1Y)
1M
+5.4%
3M
-49.7%
6M
-83.9%
YTD
-85.5%
1Y
-91.7%
3Y
-86.0%
5Y
-98.4%
Pipeline Summary
0 total trials0
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Key Facts
Market Cap$3.5M
Employees5 (+25% YoY)
CEOQuang X. Pham
IPO DateJan 20, 2023
Beta1.96
52-Week Range$0.816 – $13.01
Avg Volume360,648
ExchangeNASDAQ
Websitecadrenal.com
Ownership
Float90.3%
Shares Outstanding3.6M
Recent Insider Trades
Pham Quang XAWARD
Oct 9, 2026200,000 shares @ $0.91
Golden Lee ScottAWARD
Oct 9, 202675,000 shares @ $0.91
MURPHY JOHN RAYMONDAWARD
Oct 9, 202675,000 shares @ $0.91
Cole Jeffrey ScottAWARD
Oct 9, 2026150,000 shares @ $0.91
WILSON GLYNNAWARD
Oct 9, 202675,000 shares @ $0.91
Peers
Recent News
Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory Therapeutics
Oct 7, 2026 · globenewswire.com
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
Sep 21, 2026 · globenewswire.com
Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
Sep 3, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:05 AM